주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요

Elsevier
엘스비어와 함께 출판
Radiation oncology hypofractionation 
Article

Radiation oncology hypofractionation 

2025년 7월 2일

Preparing for changes in treatment and payment models  

Hypofractionation has demonstrated comparable outcomes to conventional regimens for prostate, bladder, breast cancers, and bone metastases. Despite strong evidence, its adoption in the U.S. lags behind other developed countries, limiting opportunities for improved patient care and operational efficiency. 

This whitepaper explores how ClinicalPath helps empower cancer centers to accelerate the adoption of hypofractionation practices, standardize care across clinical sites, and realize significant cost savings.  

Key benefits highlighted include: 

  • Dramatic increases in hypofractionated whole breast irradiation adoption. 

  • Doubling of single-fraction radiation use for bone metastases, enhancing patient convenience and resource utilization. 

  • Workflow efficiencies that saved a large integrated cancer center over $150,000 annually. 

Download the full whitepaper here

Radiation oncology hypofractionation

Download the full whitepaper here